- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
+0.20| Last Update: 05/17/13 - 4:01 PM EDT |
| Volume: 5,568,419 |
| YTD Performance: 21.50% |
| Open: $49.61 |
| Previous Close: $49.64 |
| 52 Week Range: $35.67 - $50.17 |
| Oustanding Shares: 1,013,805,980 |
| Market Cap: 50,325,328,847 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Qtr (04/13) | Qtr (07/13) | FY (04/13) | FY (04/14) | |
|---|---|---|---|---|
| Average Estimate | $1.03 | $0.90 | $3.69 | $3.82 |
| Number of Analysts | 16 | 14 | 17 | 17 |
| High Estimate | $1.04 | $0.92 | $3.70 | $3.94 |
| Low Estimate | $1.02 | $0.87 | $3.68 | $3.72 |
| Prior Year | $0.99 | $0.85 | $3.46 | $3.69 |
| Growth Rate (Year over Year) | 4.29% | 5.63% | 6.61% | 3.67% |
Medtronic downgraded at Credit SuisseMDT was downgraded from Outperform to Neutral, Credit Suisse said. Valuation call, based on a $53 price target.
Two domestic exploration and production names that scream 'buy me' are Devon and Southwestern.
Medtronic estimates, target increased at BMOMDT estimates were raised through 2015, BMO Capital said. Company continues to grow across the board. Outperform rating and new $52 price target.
Medtronic downgraded at LazardMDT was downgraded to Neutral, Lazard Capital Markets said. Stock is up 30% over the past 8 months and the company lacks near-term catalysts.
Medtronic downgraded at WunderlichMDT was downgraded from Buy to Hold, Wunderlich said. Valuation call, as the stock is up 13% year-to-date.
Medtronic upgraded at Credit SuisseMDT was upgraded from Neutral to Outperform Credit Suisse said. $50 price target. Company can grow faster than consensus expectations over the coming quarters.
JP Morgan Healthcare Conf. JPMorgan Global Healthcare Conference (Day 2 of 5) - 01/06/13 - 01/10/13 San Francisco, CA
Medtronic upgraded at MizuhoMDT was upgraded from Neutral to Buy, Mizuho said. $49 price target. Spine business should grow through new products and insurance expansion.
Portfolio Mgr. David Peltier analyzes a low-dollar stock on the verge of a potential turnaround.